Acalnib 100mg Capsule

About

Acalnib 100mg Capsule contains Acalabrutinib, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor. BTK is a crucial signaling molecule in the B-cell receptor pathway, which is often overactive in certain B-cell malignancies, promoting their growth and survival. By irreversibly binding to BTK, Acalabrutinib inhibits its activity, thereby disrupting the downstream signaling pathways that drive the proliferation and survival of malignant B-cells. This targeted action helps to reduce tumor burden and improve disease control in specific hematologic cancers.

Administered orally, Acalabrutinib is rapidly absorbed and metabolized, with its active metabolites contributing to its therapeutic effects. Its high selectivity for BTK aims to minimize off-target effects, potentially leading to a more favorable safety profile compared to less selective inhibitors. It is primarily used in patients with specific types of leukemia and lymphoma, often after prior therapies have failed or as a first-line treatment in certain settings. Regular monitoring of blood counts and other parameters is essential during treatment.

Uses

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström's Macroglobulinemia (WM)

Directions For Use

Take orally as prescribed by your doctor, usually twice daily. Swallow the capsule whole with water; do not open, crush, or chew.

Benefits

• Highly selective BTK inhibition.
• Effective in specific B-cell malignancies.
• Oral administration for patient convenience.
• May offer improved tolerability.
• Induces apoptosis in malignant B-cells.
• Contributes to sustained disease remission.

Side Effects

• Headache
• Diarrhea
• Fatigue
• Myalgia (muscle pain)
• Bruising
• Anemia
• Thrombocytopenia
• Neutropenia
• Hypertension
• Atrial fibrillation
• Increased risk of infection
• Hemorrhage (minor to major)

Safety Measures

• Alcohol - Avoid alcohol as it may increase the risk of liver toxicity and other adverse effects, potentially interfering with treatment efficacy.
• Pregnancy - This medication is generally contraindicated during pregnancy due to the risk of fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose, as the drug may pass into breast milk and harm the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be required. Regular monitoring of liver function tests is essential.
• Kidney - Use with caution in patients with renal impairment. Dosage adjustments may be necessary, and kidney function should be closely monitored.
• Lung - Monitor for signs of pulmonary toxicity, such as interstitial lung disease or pneumonitis, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.